Arrakis Therapeutics is developing drugs for neurological disorders and other diseases. Most small molecule drugs act by binding to target proteins. Arrakis is instead building upon the existing drug discovery toolkit to discover small molecule compounds that act directly on RNA. Identification of these RNA-targeted small molecules (rSMs) is achieved through Arrakis’ platform that incorporates in silico and wet lab tools to screen hundreds of targets and analyze the structure activity relationship. Arrakis’ current pipeline includes rSMs that show promise for many diseases including cancer, cardiovascular conditions and neurodegeneration. 

<p>Arrakis Therapeutics is developing drugs for neurological disorders and other diseases. Most small molecule drugs act by binding to target proteins. Arrakis is instead building upon the existing drug discovery toolkit to discover small molecule compounds that act directly on RNA. Identification of these RNA-targeted small molecules (rSMs) is achieved through Arrakis’ platform that incorporates in silico and wet lab tools to screen hundreds of targets and analyze the structure activity relationship. Arrakis’ current pipeline includes rSMs that show promise for many diseases including cancer, cardiovascular conditions and neurodegeneration. </p>


Arrakis Therapeutics

Drug notes:

About:

Jobs: